---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-120824"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T04:47:09.758552+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rein Therapeutics Q1 net loss $5.5M; Phase 2 IPF trial initiated

## Summary
- Net loss $5.5M ($0.25/shr) vs $7.1M ($0.86/shr) year ago; revenue not reported.
- Cash $7.4M at Mar 31, plus $5.28M from April warrant/private placement; runway to Sep 2025.
- Phase 2 RENEW trial of LTI-03 in IPF initiated; topline interim data expected H1 2026.
- Two U.S. patents granted for LTI-03 dry powder formulation (Apr 22, 2025).
- R&D expense $3.1M, G&A $2.5M, both down vs prior year on lower legal and LTI-01 costs.

## SEC filing metadata
- accession: 0001193125-25-120824
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312525120824/0001193125-25-120824-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312525120824/d889805d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-120824
- JSON: https://secwatch.observer/filing/0001193125-25-120824.json
- Plain text: https://secwatch.observer/filing/0001193125-25-120824.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.